Iovance Biotherapeutics (IOVA) Misses Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Iovance Biotherapeutics Reports First Quarter 2020 Financial Results and Provides a Corporate Update
May 5, 2020 4:02 PM EDTSAN CARLOS, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL and peripheral-blood lymphocyte, PBL), today reported first quarter 2020 financial results and provided a corporate update.
We continue making strong progress toward commercializing Iovance TIL for melanoma and cervical cancer indications, said Maria Fardis, Ph.D., MBA, Iovance President and Chief Executive Officer. While COVID-19 has impacted healthcare systems globally, we have been able to continue our key business operations due to dedication from our employees and... More
